The recent FDA rule change regarding Institutional Review Board (IRB) waivers for minimal risk clinical trials, effective January 22, 2024, allows exceptions from the requirement to obtain informed consent for specific minimal risk clinical investigations, provided appropriate safeguards are in place to protect participants.
The FDA’s decision aims to facilitate research that poses minimal risk to participants, allowing studies that might otherwise
be impractical to conduct due to the stringent informed consent requirements. This rule aligns with the “Common Rule” used in other federal human subject protection regulations, ensuring consistency and clarity in regulatory expectations.
Key Aspects of the Rule:
- Applicability: The rule applies to studies deemed to pose no more than minimal risk to participants, such as behavioral research or studies using existing data.
- Criteria for Waiver: To qualify for a waiver, the study must meet specific criteria, including the impracticability of conducting the research without the waiver and the assurance that the waiver will not adversely affect the rights and welfare of the participants.
- Identifiable Information: For studies involving identifiable private information or biospecimens, the rule requires that the research could not practicably be carried out without using such identifiable data.
- Post-Participation Information: When appropriate, participants must be provided with additional pertinent information after their involvement in the study.
This rule change reduces administrative burdens, potentially accelerating the pace of minimal risk research. However, it also introduces new challenges and risks. Clinical trial sponsors must be vigilant in ensuring that studies meet all waiver criteria and maintain rigorous safeguards to protect participant rights and welfare. This heightened responsibility may impact sponsors’ exposure to products liability risks, which we address in depth in an upcoming blog post.